Noida, February 15, 2025:
- To acquire R&D center at Saint-Julien-en-Genevois, France
- To add Drug Discovery & Preclinical Development capabilities in Biologics & Antibody Drug Conjugate
Jubilant Biosys Innovative Research Services Pte. Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre SA, and its affiliate entities (“PF”), for JBIRSPL to acquire 80% equity capital in JASMIN (new company incorporated by PF in France, as a Societe par Actions Simplifiee (SAS)), with remaining 20% retained by PF.
At closing of the transaction, JASMIN shall acquire Pierre Fabre’s R&D Centre (including R&D Site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL would also execute a Shareholders’ Agreement and other transition agreements with PF.
Strategic Rationale
This strategic agreement will enable Jubilant Biosys Limited to expand its footprint in Europe in areas like Biologics (mAbs) and Antibody Drug Conjugate (ADC), in addition to its existing services including integrated drug discovery services from India.
- Expands Jubilant’s addressable market in the fast-growing (20%+ CAGR) ADC/XDC segment: Expands Jubilant’s addressable market in ADC CDMO to ~$1.4 Bn. Next gen XDCs pipeline is also growing rapidly
- Enhances Jubilant Biosys Limited’s domain expertise in ADC with expanded chemistry capabilities: Complements Jubilant Biosys Limited’s payload expertise with payload-linker synthesis, bioconjugation and analytical services
- PF team have deep ADC/XDC expertise: Core team with decades of ADC experience, with history of successfully delivering several clinical candidates
- Provides strategic footprint in EU: An opportunity to significantly expand our customer connections with large pharmaceutical companies due to proximity to EU/US markets, which have a preference for local CRO interactions
- Brings together a complementary innovator customer base: The collaboration will help create significant cross-selling potential to customer bases across small-to-mid biotech and large innovator pharma
- Unique & cost-effective delivery model: Integrating the scientific expertise in Biologics at the Saint-Julien-en- Genevois site with that of small molecules at Jubilant will provide a unique & cost-effective delivery model to EU & US Companies.
Speaking on the announcement, Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Limited said, “We are thrilled to have reached this strategic agreement with Pierre Fabre. Our R&D site in Saint-Julien-en-Genevois will serve as a Center of Excellence for biologics and ADCs, located at the heart of Europe. This expansion strengthens our presence and fosters collaboration with both biotech and large pharma companies in Europe and the USA. By combining the scientific expertise in biologics and ADCs at Saint-Julien-en-Genevois with the capabilities of 1,200 scientists in India we establish a comprehensive service offering for accelerated delivery of early chemistry, discovery biology, DMPK, integrated drug discovery and CDMO for intermediates and APIs. With this strategic move, Jubilant Biosys Limited advances its “CRDMO Partner in Science” strategy and reinforces its commitment to delivering innovative solutions to global pharmaceutical customers.”
Corporate Comm India (CCI Newswire)
